RCAMU
BPMC

Rothschild & Co Asset Management US’s Blueprint Medicines BPMC Stock Holding History

Rothschild & Co Asset Management US’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-228,940
Closed -$21.2M – 290
2020
Q3 		$21.2M Sell
228,940
-40,109
-15% -$3.09M 0.38% 113
2020
Q2 		$21M Buy
269,049
+165,128
+159% +$11.2M 0.31% 130
2020
Q1 		$6.08M Buy
103,921
+7,213
+7% +$464K 0.09% 243
2019
Q4 		$7.75M Sell
96,708
-5,309
-5% -$397K 0.08% 265
2019
Q3 		$7.5M Buy
+102,017
New +$8.82M 0.08% 267

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Rothschild & Co Asset Management US's BPMC Position: Q4 2020 in Review

Rothschild & Co Asset Management US sold out of Blueprint Medicines (BPMC) in Q4 2020, closing a stake of 228,940 shares — an estimated $21.2M sold.

Rothschild & Co Asset Management US first reported a position in BPMC in Q3 2019 and held it in 5 quarters. The position peaked at $21.2M in Q3 2020. 279 funds tracked by Wall St. Rank hold BPMC as of Q4 2020.

  • Rothschild & Co Asset Management US reported no remaining Blueprint Medicines position as of Q4 2020 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 228,940 Blueprint Medicines shares in Q4 2020, an estimated $21.2M.
  • Rothschild & Co Asset Management US first reported a position in Blueprint Medicines in Q3 2019 and held it in 5 quarters.
  • Rothschild & Co Asset Management US's Blueprint Medicines position peaked at $21.2M in Q3 2020.
  • 279 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2020.

Based on Rothschild & Co Asset Management US's 13F filing for Q4 2020, filed 8 Feb 2021.